INLURIYO
GrowthNDAORALTABLET
Approved
Sep 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
INLURIYO by Eli Lilly and Company is (er) antagonist that binds to erα. First approved in 2025.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INLURIYO (imlunestrant) is an oral estrogen receptor antagonist approved by the FDA on September 25, 2025, for the treatment of estrogen receptor-positive breast cancer. It works by blocking estrogen receptor signaling, a key driver of hormone-sensitive breast cancer growth. This small-molecule therapeutic represents a new chemical entity in the estrogen receptor antagonist class.
Growth12.7 years to LOE
Early-stage launch with no direct competitors currently establishes significant market entry opportunity and likely expanding commercial team.
Mechanism of Action
(ER) antagonist that binds to ERα. In vitro, imlunestrant induced degradation of ERα, leading to inhibition of ER-dependent gene transcription and cellular proliferation in ER+ breast cancer cells. Imlunestrant demonstrated in vitro and in vivo anti-tumor activity in ER+ breast cancer xenograft…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
Started Jul 2022
113 enrolled
Healthy
Career Relevance
Working on INLURIYO places you at the forefront of a newly launched oncology product with significant unmet need in hormone receptor-positive breast cancer. Career growth opportunities are strongest in commercial roles (brand management, sales, market access) during the critical launch and growth phases, with potential long-term stability through 2039 patent protection.
Brand Manager
Worked on INLURIYO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.